Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jun 2017

Kim H R, Kang H N, Shim H S, Kim E Y, Kim J, Kim D J, Lee J G, Lee C Y, Hong M H, Kim S-M, Kim H, Pyo K-H, Yun M R, Park H J, Han J Y, Youn H A, Ahn M-J, Paik S, Kim T-M, Cho B C

Abstract excerpt

BACKGROUND: We conducted co-clinical trials in patient-derived xenograft (PDX) models to identify predictive biomarkers for the multikinase inhibitor dovitinib in lung squamous cell carcinoma (LSCC). METHODS: The PDX01-02 were established from LSCC patients enrolled in the phase II trial of dovitinib (NCT01861197) and PDX03-05 were established from LSCC patients receiving surgery. These five PDX tumors were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Clinical Trials as Topic

Share to Exome Sequencing

Share to Lung Neoplasms

Share to Quinolones

Share to Receptors, Fibroblast Growth Factor

Source

Identifiers

PMID: 28460066
DOI: 10.1093/annonc/mdx098

Genes

FGF19
FGF3
FGFR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.PMID 28460066Read ↗

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients.Semantic proximity Read ↗

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patientsSemantic proximity Read ↗

Genetic insight and therapeutic targets in squamous-cell lung cancer.Semantic proximity Read ↗

Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.Semantic proximity Read ↗

Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.Semantic proximity Read ↗

Frequency of expression and prognostic implications of emerging molecular targets in pulmonary squamous cell carcinoma.Semantic proximity Read ↗

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer.Semantic proximity Read ↗

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancerSemantic proximity Read ↗

Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancerSemantic proximity Read ↗

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.Semantic proximity Read ↗

The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.